← Back to Search

T2* Imaging for Sarcoma

N/A
Recruiting
Led By Bryan Allen, MD, PhD
Research Sponsored by Bryan Allen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG 0, 1, or 2
Pathologically confirmed Sarcoma, by biopsy or excision
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 8 weeks
Awards & highlights

Study Summary

This trial is testing if radiation therapy can change the amount of iron in a sarcoma tumor.

Who is the study for?
This trial is for adults with pathologically confirmed Sarcoma who are prescribed radiation therapy. They should be able to perform daily activities (ECOG 0, 1, or 2) and must consent to participate. Treatment should start within five weeks after surgery or biopsy.Check my eligibility
What is being tested?
The study is testing T2* MRI imaging on sarcoma tumors to see if radiation therapy affects the iron levels in these tumors. It's a small pilot study designed to explore this potential relationship.See study design
What are the potential side effects?
Since the intervention being studied is an imaging technique and not a drug, there are no direct side effects from T2* MRI itself; however, standard risks associated with MRIs apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
My sarcoma diagnosis was confirmed through a biopsy or surgery.
Select...
I am receiving radiation therapy as recommended by my doctor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in ferric iron levels detected by T2* MRI
Secondary outcome measures
Change in ferrous iron levels detected by T2* MRI

Trial Design

1Treatment groups
Experimental Treatment
Group I: T2* ImagingExperimental Treatment1 Intervention
Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.

Find a Location

Who is running the clinical trial?

Bryan AllenLead Sponsor
3 Previous Clinical Trials
116 Total Patients Enrolled
Holden Comprehensive Cancer CenterOTHER
26 Previous Clinical Trials
762 Total Patients Enrolled
1 Trials studying Sarcoma
36 Patients Enrolled for Sarcoma
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,927,332 Total Patients Enrolled
453 Trials studying Sarcoma
230,084 Patients Enrolled for Sarcoma

Media Library

T2* Imaging Clinical Trial Eligibility Overview. Trial Name: NCT03658343 — N/A
Sarcoma Research Study Groups: T2* Imaging
Sarcoma Clinical Trial 2023: T2* Imaging Highlights & Side Effects. Trial Name: NCT03658343 — N/A
T2* Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT03658343 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research venture still seeking participants?

"The clinical trial is still recruiting, according to information available on clinicaltrials.gov. This research was inaugurated in September 2018 and underwent its most recent update in August 2022."

Answered by AI

What is the current number of participants enrolled in this investigation?

"Affirmative. According to clinicaltrials.gov, this experiment is currently recruiting individuals as of August 12th 2022. It was initially posted on September 18th 2018 and requires 15 volunteers from one site."

Answered by AI
~2 spots leftby Dec 2024